1. Arnold ES, Fischbeck KH: Spinal muscular atrophy. Handb Clin Neurol 2018, 148:591-601.
2. Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, Davies KE, Leppert M, Ziter F, Wood D et al: Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990, 344(6266):540-541.
3. Borg RM, Bordonne R, Vassallo N, Cauchi RJ: Genetic Interactions between the Members of the SMN-Gemins Complex in Drosophila. PLoS One 2015, 10(6):e0130974.
4. Chaytow H, Huang YT, Gillingwater TH, Faller KME: The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 2018, 75(21):3877-3894.
5. Anderton RS, Meloni BP, Mastaglia FL, Boulos S: Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein. Molecular neurobiology 2013, 47(2):821-832.
6. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80(1):155-165.
7. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997, 16(3):265-269.
8. Wirth B: An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000, 15(3):228-237.
9. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478(7367):123-126.
10. Wu X, Wang SH, Sun J, Krainer AR, Hua Y, Prior TW: A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. Hum Mol Genet 2017, 26(14):2768-2780.
11. Son HW, Yokota T: Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy. Methods Mol Biol 2018, 1828:57-68.
12. Long JC, Caceres JF: The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009, 417(1):15-27.
13. Anko ML: Regulation of gene expression programmes by serine-arginine rich splicing factors. Semin Cell Dev Biol 2014, 32:11-21.
14. Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, Chabot B: hnRNP proteins and splicing control. Adv Exp Med Biol 2007, 623:123-147.
15. Ule J, Stefani G, Mele A, Ruggiu M, Wang X, Taneri B, Gaasterland T, Blencowe BJ, Darnell RB: An RNA map predicting Nova-dependent splicing regulation. Nature 2006, 444(7119):580-586.
16. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR: Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008, 82(4):834-848.
17. Wee CD, Havens MA, Jodelka FM, Hastings ML: Targeting SR proteins improves SMN expression in spinal muscular atrophy cells. PLoS One 2014, 9(12):e115205.
18. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR: Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010, 24(15):1634-1644.
19. Buckanovich RJ, Posner JB, Darnell RB: Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993, 11(4):657-672.
20. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H: A mouse model for spinal muscular atrophy. Nature genetics 2000, 24(1):66-70.
21. Graus F, Rowe G, Fueyo J, Darnell RB, Dalmau J: The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 1993, 150(2):212-214.
22. Yang YY, Yin GL, Darnell RB: The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A 1998, 95(22):13254-13259.
23. Jensen KB, Dredge BK, Stefani G, Zhong R, Buckanovich RJ, Okano HJ, Yang YY, Darnell RB: Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron 2000, 25(2):359-371.
24. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 2001, 98(17):9808-9813.
25. Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D, Donadoni C, Salani S, Riboldi G, Magri F et al: Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med 2012, 4(165):165ra162.
26. Hoy SM: Nusinersen: First Global Approval. Drugs 2017, 77(4):473-479.
27. Hoy SM: Onasemnogene Abeparvovec: First Global Approval. Drugs 2019, 79(11):1255-1262.
28. Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, Swoboda KJ, Kiernan MC: Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2017, 81(3):355-368.
29. Ward AJ, Cooper TA: The pathobiology of splicing. J Pathol 2010, 220(2):152-163.
30. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40(12):1413-1415.
31. Lim KH, Ferraris L, Filloux ME, Raphael BJ, Fairbrother WG: Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. Proc Natl Acad Sci U S A 2011, 108(27):11093-11098.
32. Love JE, Hayden EJ, Rohn TT: Alternative Splicing in Alzheimer's Disease. J Parkinsons Dis Alzheimers Dis 2015, 2(2).
33. Aoyagi Y, Kobayashi H, Tanaka K, Ozawa T, Nitta H, Tsuji S: A de novo splice donor site mutation causes in-frame deletion of 14 amino acids in the proteolipid protein in Pelizaeus-Merzbacher disease. Ann Neurol 1999, 46(1):112-115.
34. Rogawski MA, Donevan SD: AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 1999, 79:947-963.
35. Chen YC, Chang JG, Jong YJ, Liu TY, Yuo CY: High expression level of Tra2-beta1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice. PLoS One 2015, 10(3):e0120721.
36. Qin M, Wei G, Sun X: Circ-UBR5: An exonic circular RNA and novel small nuclear RNA involved in RNA splicing. Biochem Biophys Res Commun 2018, 503(2):1027-1034.
37. Ludlow AT, Wong MS, Robin JD, Batten K, Yuan L, Lai TP, Dahlson N, Zhang L, Mender I, Tedone E et al: NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 2018, 9(1):3112.
38. Dredge BK, Darnell RB: Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. Mol Cell Biol 2003, 23(13):4687-4700.
39. Leggere JC, Saito Y, Darnell RB, Tessier-Lavigne M, Junge HJ, Chen Z: NOVA regulates Dcc alternative splicing during neuronal migration and axon guidance in the spinal cord. Elife 2016, 5.
40. Yuan Y, Xie S, Darnell JC, Darnell AJ, Saito Y, Phatnani H, Murphy EA, Zhang C, Maniatis T, Darnell RB: Cell type-specific CLIP reveals that NOVA regulates cytoskeleton interactions in motoneurons. Genome Biol 2018, 19(1):117.
41. Herve M, Ibrahim EC: MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia. Dis Model Mech 2016, 9(8):899-909.
42. Ruggiu M, Herbst R, Kim N, Jevsek M, Fak JJ, Mann MA, Fischbach G, Burden SJ, Darnell RB: Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing. Proc Natl Acad Sci U S A 2009, 106(9):3513-3518.
43. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB: CLIP identifies Nova-regulated RNA networks in the brain. Science 2003, 302(5648):1212-1215.
44. Schrank B, Gotz R, Gunnersen JM, Ure JM, Toyka KV, Smith AG, Sendtner M: Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 1997, 94(18):9920-9925.
45. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G: The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol 2002, 14(3):305-312.
46. Fallini C, Bassell GJ, Rossoll W: Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res 2012, 1462:81-92.
47. Groen EJN, Perenthaler E, Courtney NL, Jordan CY, Shorrock HK, van der Hoorn D, Huang YT, Murray LM, Viero G, Gillingwater TH: Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet 2018, 27(16):2851-2862.
48. Dombert B, Sivadasan R, Simon CM, Jablonka S, Sendtner M: Presynaptic localization of Smn and hnRNP R in axon terminals of embryonic and postnatal mouse motoneurons. PLoS One 2014, 9(10):e110846.
49. Singh RN, Howell MD, Ottesen EW, Singh NN: Diverse role of survival motor neuron protein. Biochimica et biophysica acta Gene regulatory mechanisms 2017, 1860(3):299-315.
50. Tadesse H, Deschenes-Furry J, Boisvenue S, Cote J: KH-type splicing regulatory protein interacts with survival motor neuron protein and is misregulated in spinal muscular atrophy. Hum Mol Genet 2008, 17(4):506-524.